This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Eylea

Regeneron Pharmaceuticals, Inc.

Drug Names(s): VEGF Trap-Eye, BAY86-5321, Vascular Endothelial Growth Factor Trap (Ocular)

Description: Due to partnership considerations, BioMedTracker has separate drug profiles for the ocular and oncological indications of the VEGF Trap. Please also see VEGF Trap - Oncology.

The VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A and related placental growth factor (PlGF).The VEGF Trap-Eye is designed to block the interaction of these growth factors with cell-surface receptors, thereby preventing the subsequent formation of the new blood vessels that play an important role in the development of eye diseases such as wet AMD.

Deal Structure: Revenue splits are BioMedTracker estimates.

Regeneron and Bayer
In October 2006, Bayer and Regeneron entered into a collaboration agreement for the global development, and commercialization outside the U.S., of the VEGF Trap for the treatment of eye disease by local administration (VEGF Trap-Eye). The companies will jointly commercialize the VEGF Trap-Eye outside the U.S and will share equally in profits from ex-U.S. sales. Within the U.S., Regeneron has exclusive commercialization rights in all indications and will retain 100%of all profits from any such sales.

Principal financial terms of the agreement include: